• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop bioink for 3D-printed pills

February 9, 2017 By Sarah Faulkner

Researchers develop bioink for 3D-printed pillsResearchers at the University of California Los Angeles have developed a viable bioink made out of hyaluronic acid for 3D-printed pills.

In this study, researchers used an inket technique to 3D print the pills, citing the method’s speed and ability to print at room temperature. Its speed is important for scalability and mass production, while the ability to print at room temperature ensures that active pharmaceutical ingredients aren’t damaged in the process of printing.

The printable bioink is composed of hyaluronic acid, which is the primary component of skin and connective tissues. The researchers added a photoinitator to the acid so that it solidifies when it comes into contact with light.

The mixture of hyaluronic acid and photoinitator is used to fill preformed tablets, according to the team.

The hyaluronic acid is laced with Ropinirole hydrochloric acid – a stimulant used to treat muscle problems associated with Parkinson’s disease. The researchers chose Ropinirole hydrochloric acid as the active pharmaceutical ingredient for its hydrophilic properties, which makes it water-soluble and measurable as it dissolves.

The team used a piezoelectric nozzle to deposit the active pharmaceutical ingredient.

The researchers measured the pills’ dissolution rate in an acidic substance that mimicked stomach contents. Within 15 minutes, the pill released 60% of its contents and after another 15 minutes, an additional 20% was released. Drug release peaked at 1 hour, the team reported.

Improving translation between pharmaceutical substances and the 3D-printing process could establish 3D-printing as a viable method for pharmaceutical production, the team argued.

Filed Under: Pharmaceuticals, Research & Development Tagged With: University of California Los Angeles

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS